L&G PHARMA BREAKTHROUGH UCITS ETF (ACC., USD) BIOT.GB

The L&G Pharma Breakthrough UCITS ETF is a passively managed equity fund that aims to replicate the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (USD). The index tracks publicly traded biotechnology companies worldwide which are actively engaged in the research, development, or manufacture of orphan drugs - medicines for rare diseases.

Companies must meet criteria related to size and trading liquidity to be eligible, and the index is reconstituted semi-annually and equally weighted, with monthly adjustments to prevent any single constituent exceeding 15 % of the index.

The fund invests exclusively in the equity of these companies, offering exposure to the global biotech sector focused on orphan drugs. It employs full physical replication, purchasing and holding the same securities in similar proportions to those in the index.

The ETF is issued by Legal & General via LGIM Managers (Europe) Limited, domiciled in Ireland, and structured as a UCITS fund for the European market.